NewAmsterdam Pharma (NAMS) Non-Current Deffered Revenue (2022 - 2024)

NewAmsterdam Pharma has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $222000.0 in Q2 2024.

• Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $222000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $222000.0 (changed N/A YoY) and the FY2023 annual result came in at $1.0 million, down 78.74% from the prior year.
• Non-Current Deffered Revenue retreated to $222000.0 in Q2 2024 per NAMS's latest filing, from $444000.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $4.8 million in Q4 2022 and troughed at $222000.0 in Q2 2024.
• A 3-year average of $1.6 million and a median of $731500.0 in 2023 frame the typical range for Non-Current Deffered Revenue.
• The widest YoY moves for Non-Current Deffered Revenue: up 78.74% in 2023, down 78.74% in 2023.
• Over 3 years, Non-Current Deffered Revenue stood at $4.8 million in 2022, then plunged by 78.74% to $1.0 million in 2023, then tumbled by 78.21% to $222000.0 in 2024.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $222000.0, $444000.0, and $1.0 million for Q2 2024, Q1 2024, and Q4 2023 respectively.